Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Lawrence A Loeb" Clear advanced filters

  • The mutator phenotype describes a process by which tumour cells are proposed to evolve genetic alterations that contribute to the acquisition of the various attributes that are required for tumour progression. Here, Lawrence Loeb updates this hypothesis, focusing on how DNA sequencing has informed the current view of the mutator phenotype in cancer.

    • Lawrence A. Loeb
    Reviews
    Nature Reviews Cancer
    Volume: 11, P: 450-457

  • Recent evidence has implicated APOBEC3B as a source of mutations in cervical, bladder, lung, head and neck, and breast cancers. APOBEC enzymes normally function in innate immune responses, including those that target retroviruses, suggesting links between mutagenesis, immunity and viral infection in the process of cancer development.

    • Kawai J Kuong
    • Lawrence A Loeb
    News & Views
    Nature Genetics
    Volume: 45, P: 964-965

  • Single-cell DNA sequencing of two breast-cancer types has shown extensive mutational variation in individual tumours, confirming that generation of genetic diversity may be inherent in how tumours evolve. See Article p.155

    • Edward J. Fox
    • Lawrence A. Loeb
    News & Views
    Nature
    Volume: 512, P: 143-144

  • The molecularly targeted therapy paradigm has led to improvements in the management of patients with cancer. Responses to targeted therapies are, however, mostly short-lived, owing to inherent or acquired resistance, which in most cases relates to the outgrowth of pre-existent rare subclones harbouring resistance mutations. Our current understanding of this concept is reviewed herein; how knowledge of pre-existing resistance mechanism obtained through the use of ultra-sensitive sensitive DNA-sequencing assays might be best exploited to improve personalized medicine is discussed.

    • Michael W. Schmitt
    • Lawrence A. Loeb
    • Jesse J. Salk
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 13, P: 335-347